Nature's Sunshine Products (NATR)
NASDAQ:NATR
Top Page
Nature's Sunshine Products
(NASDAQ:NATR)
Select Model
Select Model
Rating:61Neutral
Price Target:
$26.00
▲(9.98% Upside)
Action:ReiteratedDate:03/12/26
The score is led by solid strategic/operational momentum and constructive 2026 guidance from the earnings call, supported by a strong balance sheet, but is held back by the weak cash-flow signal in the financial statement scoring and currently soft technical momentum; valuation appears neutral at a ~19.9 P/E.
Positive Factors
Balance sheet strength
Nature's Sunshine's low leverage, sizable cash buffer and improved ROE provide durable financial flexibility. This supports continued investment in digital and product initiatives, opportunistic buybacks or M&A, and cushions the business against cyclical softness without immediate refinancing pressure.
Negative Factors
Weak cash generation in 2025
A sudden collapse in cash generation undermines self-funding of investments and capital returns. Even with healthy cash reserves, recurring weak cash conversion raises concerns about working-capital management, reinvestment needs, or one-off items that could recur and constrain strategic flexibility.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance sheet strength
Nature's Sunshine's low leverage, sizable cash buffer and improved ROE provide durable financial flexibility. This supports continued investment in digital and product initiatives, opportunistic buybacks or M&A, and cushions the business against cyclical softness without immediate refinancing pressure.
Read all positive factors
Nature's Sunshine Products (NATR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$413.88M
Dividend YieldN/A
Average Volume (3M)135.40K
Price to Earnings (P/E)23.0
Beta (1Y)0.50
Revenue Growth6.62%
EPS Growth-7.85%
CountryUS
Employees819
SectorConsumer Defensive
Sector Strength42
IndustryPackaged Foods
Share Statistics
EPS (TTM)0.30
Shares Outstanding17,507,608
10 Day Avg. Volume180,753
30 Day Avg. Volume135,401
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)2.41
Price to Sales (P/S)0.81
P/FCF Ratio13.47
Enterprise Value/Market Cap0.82
Enterprise Value/Revenue0.71
Enterprise Value/Gross Profit1.02
Enterprise Value/Ebitda8.78
Forecast
1Y Price Target
$33.00Price Target Upside39.59% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.97
Revenue Forecast (FY)$494.86M
Nature's Sunshine Products Business Overview & Revenue Model
Company Description
Nature's Sunshine Products, Inc., a natural health and wellness company, primarily manufactures and sells nutritional and personal care products in Asia, Europe, North America, Latin America, and internationally. It offers general health products ...
How the Company Makes Money
Nature’s Sunshine makes money primarily by selling health and wellness products (dietary supplements and personal care items) through its distribution network. A key revenue stream is product sales to and through independent distributors (and, whe...
Nature's Sunshine Products Earnings Call Summary
Earnings Call Date:Mar 10, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 12, 2026
Earnings Call Sentiment Positive
The call reflected a predominantly positive performance backdrop: record annual sales, strong digital acceleration, improving margins, meaningful adjusted EBITDA and cash-generation improvement, plus a healthy balance sheet and a clear ambition toward a $1B revenue target. Management is deliberately investing to accelerate growth (digital, product innovation, geographic expansion), which tempers near-term EBITDA progression and increases SG&A. Key risks noted were APAC lumpiness, potential channel conflict, inventory and macro/geopolitical uncertainty (tariffs, inflation, war impacts). On balance, the operational and financial momentum plus strategic clarity outweigh the manageable near-term costs and risks.Positive Updates
Record Annual and Strong Quarterly Sales
Full-year 2025 net sales of $480.1M, a company record and up 6% year-over-year (5% ex-FX); Q4 net sales $123.8M, up 5% year-over-year (4% ex-FX) and the company’s strongest fourth quarter on record.
Negative Updates
Rising SG&A and Increased Marketing Spend
Q4 SG&A rose to $48.4M from $43.7M year-over-year; SG&A as a percent of sales increased to 39.1% from 35.7%, driven primarily by higher digital ad spend, variable costs tied to sales growth and nonrecurring items; quarterly SG&A expected at $46M–$48M in 2026.
Read all updates
Q4-2025 Updates
Positive
Negative
Record Annual and Strong Quarterly Sales
Full-year 2025 net sales of $480.1M, a company record and up 6% year-over-year (5% ex-FX); Q4 net sales $123.8M, up 5% year-over-year (4% ex-FX) and the company’s strongest fourth quarter on record.
Read all positive updates
Company Guidance
Nature's Sunshine guided 2026 net sales of $500–$515 million (4–7% growth versus $480.1M in FY2025) and adjusted EBITDA of $50–$54 million (1–9% growth versus $49.4M in 2025), noting the range reflects measured investments in technology, customer acquisition, geographic expansion and product innovation that will temper near‑term EBITDA growth; they expect gross margin to modestly improve and settle in the upper‑72% range and quarterly SG&A of $46–$48M. Management reiterated expectations for continued mid‑single‑digit revenue growth across North America, APAC and Europe while flagging tariff/inflation uncertainty, and emphasized digital momentum (North America digital +47% Q4 YoY; website subscriptions +260 bps to 47% of digital revenue; TikTok auto‑ship 25% of TikTok revenue; China auto‑ship 18% of revenue; Japan auto‑ship ~50% of sales). The balance sheet supports the plan with $93.9M cash, zero debt, inventory of $68.3M (moderate increase expected), $35.3M net cash from operations in 2025, and $17.4M remaining on the share repurchase program.Nature's Sunshine Products Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
80
Positive
Cash Flow
38
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 480.14M | 454.36M | 445.32M | 421.91M | 444.08M |
| Gross Profit | 333.88M | 324.69M | 321.13M | 299.76M | 328.62M |
| EBITDA | 38.59M | 32.79M | 32.09M | 31.15M | 43.23M |
| Net Income | 19.52M | 7.70M | 15.08M | -390.00K | 28.85M |
Balance Sheet | |||||
| Total Assets | 261.15M | 240.85M | 249.77M | 229.78M | 258.87M |
| Cash, Cash Equivalents and Short-Term Investments | 93.89M | 84.70M | 82.37M | 60.03M | 86.18M |
| Total Debt | 18.90M | 14.20M | 14.92M | 19.18M | 22.99M |
| Total Liabilities | 99.59M | 79.86M | 90.23M | 82.73M | 97.47M |
| Stockholders Equity | 161.55M | 155.31M | 154.06M | 142.91M | 158.20M |
Cash Flow | |||||
| Free Cash Flow | 28.84M | 14.33M | 30.75M | -6.92M | 27.94M |
| Operating Cash Flow | 35.32M | 25.30M | 41.23M | 710.00K | 34.61M |
| Investing Cash Flow | -12.64M | -10.97M | -10.48M | -7.63M | -6.61M |
| Financing Cash Flow | -17.61M | -9.90M | -7.96M | -16.25M | -31.72M |
Nature's Sunshine Products Technical Analysis
Negative
23.64
Price Trends
25.31
Negative
22.94
Positive
19.20
Positive
Market Momentum
-0.59
Positive
38.27
Neutral
37.90
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NATR, the sentiment is Negative. The current price of 23.64 is below the 20-day moving average (MA) of 24.95, below the 50-day MA of 25.31, and above the 200-day MA of 19.20, indicating a neutral trend. The MACD of -0.59 indicates Positive momentum. The RSI at 38.27 is Neutral, neither overbought nor oversold. The STOCH value of 37.90 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NATR.
Nature's Sunshine Products Risk Analysis
Nature's Sunshine Products disclosed 25 risk factors in its most recent earnings report. Nature's Sunshine Products reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Nature's Sunshine Products Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
63 Neutral | $1.53B | 5.80 | -36.19% | ― | -0.78% | 265.56% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
62 Neutral | $765.78M | 27.76 | 9.29% | ― | 11.31% | 99.83% | |
61 Neutral | $413.88M | 22.99 | 12.18% | ― | 6.62% | -7.85% | |
56 Neutral | $54.88M | 70.54 | 24.97% | 2.81% | 16.77% | 143.30% | |
53 Neutral | $318.94M | 33.56 | 2.03% | ― | 5.88% | -68.62% | |
46 Neutral | $16.86M | -2.11 | -17.43% | ― | 18.19% | -35.22% |
* Consumer Defensive Sector Average
NATR
Nature's Sunshine Products
23.64
11.03
87.47%
HLF
Herbalife
14.76
6.14
71.23%
NAII
Natural Alternatives International
2.73
-0.72
-20.87%
STKL
SunOpta
6.47
1.44
28.63%
USNA
USANA Health
17.28
-10.88
-38.64%
LFVN
LifeVantage
4.29
-10.39
-70.77%
Nature's Sunshine Products Corporate Events
Business Operations and StrategyExecutive/Board ChangesFinancial Disclosures
Nature’s Sunshine Reports Strong Q4 and 2025 Results
Positive
Mar 11, 2026
Nature’s Sunshine reported strong results for the fourth quarter and full year ended December 31, 2025, with Q4 net sales up 4.7% to $123.8 million and gross margin improving to 72.5% on cost savings and favorable market mix. GAAP net income...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.